GLP-1, GIP & Glucagon: The Incretin Receptors Explained

For laboratory research use only; not for human consumption.

Three receptors, one organizing framework

Three G-protein-coupled receptors sit at the center of nearly every metabolic-research peptide discussion: the GLP-1 receptor (GLP-1R), the GIP receptor (GIPR) and the glucagon receptor (GCGR). They are structurally related, they signal through overlapping intracellular pathways, and the number of them a given compound engages is the biggest single differentiator among the major research peptides. This article explains each receptor, what they share, where they differ, and how that maps onto the compounds used in assays. Compound-level detail is in the GLP-1 receptor agonists in research overview.

What the incretin effect is

The term "incretin" comes from an observation that glucose taken by mouth produces a larger insulin response than the same glucose given intravenously. Gut-derived hormones released after nutrient arrival account for the difference. The two classical incretins are GLP-1, secreted by intestinal L-cells, and GIP, secreted by K-cells. Both stimulate insulin release in a glucose-dependent manner, meaning the effect fades as glucose falls. Both are also cleared quickly: native GLP-1 is cut by the enzyme dipeptidyl peptidase-4 (DPP-4) within minutes. That rapid inactivation is the reason research analogs are engineered with amino acid substitutions or fatty-acid side chains, which protect against DPP-4 and, in some cases, promote binding to serum albumin so that the molecule persists in solution and in assays.

GLP-1: the reference incretin receptor

The GLP-1 receptor is a class B (secretin-family) GPCR expressed in pancreatic islet cells, the gastrointestinal tract and regions of the central nervous system. In research models, GLP-1R activation is studied for its role in glucose-dependent insulin secretion, gastric emptying and satiety signaling. Its signaling is primarily through Gs coupling, which activates adenylyl cyclase, raises intracellular cAMP and engages protein kinase A, with additional contributions from arrestin recruitment and other branches. Semaglutide is the reference GLP-1-selective agonist for this work; its research overview covers its structure, and what is semaglutide gives a shorter introduction.

GIP: the second incretin

The GIP receptor is the other classical incretin receptor. It is expressed alongside GLP-1R in the gut and pancreas, but its downstream effects differ in ways researchers are still mapping, including questions about adipose-tissue signaling that have no clean GLP-1 parallel. Compounds engaging both receptors are studied to characterize whether combined GIP/GLP-1 agonism produces effects that neither receptor alone reproduces. Tirzepatide is the primary dual agonist in this line of research; see the tirzepatide research overview, and is tirzepatide a peptide for its structural class.

Glucagon receptor: the third target

The glucagon receptor is more distantly related within the same class B family. It is classically associated with hepatic glucose output and energy-expenditure pathways rather than direct insulin secretion, so on its own it pulls in a direction that appears opposite to the incretins. That is why adding glucagon-receptor agonism to a GIP/GLP-1 backbone is a deliberate design choice and defines the triple-agonist research category. Retatrutide is studied for this profile, and retatrutide vs. tirzepatide discusses how the added receptor changes the questions asked.

Shared signaling machinery, different outcomes

All three receptors couple to Gs and raise cAMP, so a cAMP accumulation assay in a cell line expressing a single receptor is the standard way to measure agonist activity at that receptor. Differences in outcome come from where each receptor is expressed and which other signaling branches it engages, not from a fundamentally different second messenger. Four practical points follow for assay design:

• Cell line choice sets the answer. A line expressing only GLP-1R cannot report GIP or glucagon activity; engineered lines expressing one receptor each are used to profile selectivity.
• Potency and efficacy are separate. A compound may be a full agonist at one receptor and a partial agonist at another, so a single EC50 does not summarize it.
• Species matter. Receptor sequences and ligand affinities differ between human and rodent receptors, which affects how results transfer between models.
• Biased signaling is possible. Two agonists can produce different balances of cAMP and arrestin signaling at the same receptor.

Amylin as a neighboring pathway

Amylin acts through a different receptor family (the calcitonin receptor in complex with accessory RAMP proteins), so it is not an incretin pathway, but it is frequently studied next to one. Cagrilintide is a long-acting amylin analog used for combination-mechanism work with incretin agonists; see its overview and the combination article.

How the ligands are built to engage them

All three native ligands are related peptide hormones, which is why a single sequence can be tuned to bind more than one receptor. GLP-1, GIP and glucagon share sequence features in their N-terminal region, the part that activates the receptor, while the C-terminal region contributes mainly to binding affinity and selectivity. Dual and triple agonists exploit this overlap: they are built on a scaffold that preserves the activating N-terminus, then adjust residues along the chain to set the balance of activity at each receptor. The same logic explains why a single substitution can shift selectivity, and why the exact sequence on the certificate matters; see understanding amino acid sequences.

Duration is engineered separately. Substituting an amino acid at the DPP-4 cleavage site, and attaching a fatty-acid chain that binds albumin, are the two common approaches. In vitro, albumin in the assay buffer can shift apparent potency of such compounds, so buffer composition should be stated when results are compared between laboratories.

Why receptor selectivity drives compound choice

Receptor selectivity is the main variable that determines what an experimental model can answer. A compound that engages only GLP-1R isolates that pathway cleanly, which suits a question specific to GLP-1 signaling. A dual or triple agonist is the right tool when the question is how several pathways interact or combine on a shared readout, such as cAMP accumulation in a given cell model. Choosing the wrong compound for the question, such as a GLP-1-only agonist in a study built to probe GIP-receptor contribution, does not merely weaken the result; it can make the data uninterpretable against the hypothesis.

Side-by-side commentary is available in semaglutide vs. tirzepatide and the four-compound comparison.

Verifying the compound you are studying

Selectivity claims assume the vial contains the intended sequence. Because these are long peptides with engineered residues and, in some cases, fatty-acid chains, identity should be confirmed by mass spectrometry in addition to HPLC purity; see understanding amino acid sequences and HPLC vs. mass spectrometry. Batch records are on the CoA page, and nominal stock concentrations can be computed with the calculator; the metabolic-category vials are listed under metabolic research.

Frequently asked questions

What are the incretin receptors?

Two classical ones, the GLP-1 receptor and the GIP receptor, activated by gut hormones that amplify glucose-dependent insulin secretion. The glucagon receptor is related and often discussed with them.

What type of receptors are they?

Class B (secretin-family) G-protein-coupled receptors, signaling mainly through Gs, adenylyl cyclase and cAMP.

How do GLP-1 and GIP differ?

They are secreted by different intestinal cells and have overlapping but not identical downstream effects. GIP's role in adipose-tissue signaling is one area with no clean GLP-1 parallel.

Why include the glucagon receptor in the same discussion?

It is a close relative that signals through the same second messenger. Adding glucagon-receptor agonism to a GIP/GLP-1 backbone defines the triple-agonist research category.

Which compounds map to which receptors?

Semaglutide is GLP-1R-selective, tirzepatide engages GIPR and GLP-1R, and retatrutide engages GIPR, GLP-1R and GCGR.

Why are research analogs engineered?

Native GLP-1 is degraded within minutes by DPP-4. Substitutions and fatty-acid side chains protect against that and can promote albumin binding.

How is receptor activity measured in the lab?

Commonly with cAMP accumulation assays in cell lines expressing a single receptor, which allows selectivity to be profiled receptor by receptor.

Is amylin an incretin?

No. It acts through calcitonin-receptor/RAMP complexes. It is studied alongside incretin pathways, for example with cagrilintide.

For laboratory research use only; not for human consumption.

Research Use Only. Supplied strictly for laboratory research and development. Not for human or veterinary use, consumption, or any diagnostic purpose. This article is research education, not usage guidance.

References

1. V8 Peptides. GLP-1 receptor agonists in research.
2. V8 Peptides. Semaglutide research overview.
3. V8 Peptides. Tirzepatide research overview.
4. V8 Peptides. Retatrutide research overview.
5. V8 Peptides. Retatrutide vs. tirzepatide.
6. V8 Peptides. Cagrilintide research overview.